Pfizer and GlaxoSmithKline—the number one and two drug companies by pharmaceutical sales—are reshaping their R&D organizations, with job cuts likely.

Pfizer’s biannual drug pipeline update highlighted candidates in Phase III development, most of which are in its high-priority research areas of oncology, pain, inflammation, diabetes, schizophrenia, and Alzheimer’s disease.

Separately, Martin Mackay, president of Pfizer global R&D, told managers in an internal memo that Pfizer is ending research in anemia, bone health, obesity, gastrointestinal disease, and some cardiovascular diseases. “We are investing in the most promising disease areas, where there is strong unmet medical need, favorable markets, and an opportunity to advance medical science,” Mackay said. Read the full story

Popularity: 5% [?]